GREENSBORO – Qorvo Biotechnologies has landed one other contract – this one price greater than $4 million – from the Nationwide Institutes of Well being to proceed growth of its diagnostic take a look at platform which might be used for COVID-related testing.
The corporate is a subsidiary of Qorvo (Nasdaq: ORVO), a semiconductor and radio frequency product firm.
The biotech group landed a $24.4 million contract final yr to assist growth of its Qorvo Omnia platform. The brand new funding will probably be used for additional medical trials and market launch of two exams:
- SARS-CoV-2/ Flu Combo Assay
- SARS-CoV-2 Antigen Pooling
The SARS-CoV-2/Flu Combo Assay will concurrently detect and differentiate between SARS-CoV-2, Flu A and Flu B in an all-in-one take a look at utilizing a single swab pattern in roughly 20 minutes, in response to the corporate.
The antigen pooling utility will enable as much as six samples to be processed collectively and examined on the similar time, Qorvo Biotechnologies added.
“At this time’s COVID testing market is demanding top quality testing infrastructure on the level of care (POC), with automated workflow, menu growth and scalability to serve future wants of the pandemic,” Philip Chesley, president of Qorvo Biotechnologies, stated in a press release on Monday. “This contract award and continued RADx assist allow Qorvo to extra successfully deal with the increasing necessities of various finish use settings.”
